Compare Asuransi Maximus Graha Persada Tbk. (ASMI) vs Brigit Biofarmaka Teknologi Tbk. (OBAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asuransi Maximus Graha Persada Tbk. vs Brigit Biofarmaka Teknologi Tbk. — how do they compare? Asuransi Maximus Graha Persada Tbk. trades at Rp17 (market cap 143.33B, 2.24M 24h volume), while Brigit Biofarmaka Teknologi Tbk. trades at Rp242 (market cap 164.65B, 34.4K 24h volume). The key difference: Asuransi Maximus Graha Persada Tbk. and Brigit Biofarmaka Teknologi Tbk. are close in size by market cap, and Asuransi Maximus Graha Persada Tbk. is more actively traded (2.24M versus 34.4K). Which is the better fit depends on your goals.
| ASMI | OBAT | |
|---|---|---|
Market Cap | 143.33B | 164.65B |
Volume | 2.24M | 34.4K |
Lot | 22.44K | 344 |
Turnover | 38.14M | 8.31M |
Average Price | 17 | 241.65 |
Value | 38.14M | 8.31M |
Indicative Equilibrium Price | 17 | 238 |
Indicative Equilibrium Volume | 68.38K | 100 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Asuransi Maximus Graha Persada Tbk.
PT Asuransi Kresna Mitra Tbk (the Company) formerly name PT Maskapai Asuransi Patriot was established dated April 24, 1956 in Jakarta based on Deed No.187 of Meester Raden Soedja notary. The Deed of Establishment was approved by the Minister of Justice of the Republic Indonesia through Decision Letter No. J.A.5/49/19 dated June 25, 1956 and reaffirmed in decision Letter No. C2-HT.01.01-A.8725 dated November 20, 1992, and was published in supplement No.31 additional No.1665 of the state Gazette of the Republic of Indonesia dated April 16,1993.
Read more on ASMI →About Brigit Biofarmaka Teknologi Tbk.
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →
